Document is current
Any future updates will be listed below
-
Authors
Akhtar, Akil
Styles, Tiffany M.
Gu, Chunyang
León, André Nicolás
Tharp, Gregory K. https://orcid.org/0000-0003-3075-755X
Stokdyk, Kasey
Abbad, Anass
Hirst, Cora
Strohmeier, Shirin
Neumann, Gabriele
Richey, Sara T.
Ferguson, James A.
Mala, Uchurappa
Ahmed, Hasan
Han, Julianna https://orcid.org/0000-0002-3402-2609
Carreño, Juan Manuel
Davis, Carl W. https://orcid.org/0000-0002-6049-0684
Antia, Rustom https://orcid.org/0000-0001-7991-614X
Palese, Peter
Ward, Andrew B. https://orcid.org/0000-0001-7153-3769
Kawaoka, Yoshihiro https://orcid.org/0000-0001-5061-8296
Krammer, Florian https://orcid.org/0000-0003-4121-776X
Ahmed, Rafi https://orcid.org/0000-0002-9591-2621
Amara, Rama R. https://orcid.org/0000-0002-6309-6797
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 12 September 2025
First Online: 15 October 2025
Competing interests
: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines (including cHAs) and influenza virus therapeutics which list F.K. and P.P. as coinventors and F.K. has received royalty payments from some of these patents. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. F.K. is cofounder and scientific advisory board member of Castlevax. F.K. has consulted for Merck, GSK, Sanofi, Curevac, Seqirus and Pfizer and is currently consulting for Third Rock Ventures, Gritstone and Avimex. The laboratory of F.K. is also collaborating with Dynavax on influenza vaccine development and with VIR on influenza virus therapeutics. J.H. and A.B.W. are consultants for Third Rock Ventures. The laboratory of A.B.W. received unrelated sponsored research agreements from Third Rock Ventures during the conduct of the study. The other authors declare no competing interests.
